Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to human vascular endothelial growth factor and inhibits angiogenesis and hence tumour growth. It is available in the US and other countries for the treatment of several types of cancer, including glioblastoma that has recurred after previous treatment.
Two prospective phase II trials have evaluated bevacizumab 10mg/kg every 2 weeks for the treatment of previously treated glioblastoma. In the randomized, noncomparative, multicentre AVF3708g trial in patients with glioblastoma in first or second relapse, the rate of progression-free survival at 6 months was 42.6% and the objective response rate was 28.2% in recipients of bevacizumab alone (n = 85). In the bevacizumab plus irinotecan treatment arm (n=82), the 6-month progression-free survival rate was 50.3% and the objective response rate was 37.8%. These rates were all significantly higher than historical control data.
In the supporting, single-arm, single-centre, phase II NCI 06-C-0064E trial of bevacizumab in patients with glioblastoma that had recurred after radiotherapy and temozolomide chemotherapy (n = 48), the rate of progression-free survival at 6 months was 29% and the overall response rate based on Macdonald criteria was 35%.
Given the nature of the disease, bevacizumab was generally well tolerated in these two phase II trials. In the AVF3708g trial, grade 3 or higher treatment-emergent adverse events occurred in 46.4% of bevacizumab and 65.8% of bevacizumab plus irinotecan recipients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Omuro AMP, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007 Jul; 6(7): 1909–19
Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 2007–2008 (years of data collected 2000–2004) [online]. Available from URL: http://www.cbtrus.org/reports//2007-2008/2007report.pdf [Accessed 2009 Sep 14]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers V.2.2009 [online]. Available from URL: http://www.nccn.org [Accessed 2009 Sep 14]
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999 Aug; 17(8): 2572–8
de Groot JF, Yung WKA. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008 Sep–Oct; 14(5): 279–85
Chaudhry IH, O’Donovan DG, Brenchley PEC, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001 Oct; 39(4): 409–15
Zhou YH, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003 Aug 15; 9(9): 3369–75
Avastin® (bevacizumab) solution for intravenous infusion: US prescribing information. South San Francisco (CA): Genentech, Inc., 2009 Jul
Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67(12): 1793–9
Frampton JE, Keating GM. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma. Biodrugs 2008; 22(2): 113–20
Wagstaff AJ, Keam SJ, McCormack PL. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer. Biodrugs 2009; 23(3): 187–96
Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5(1): 43–60
Chinot O, de La Motte Rouge T, Moore N, et al. Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial [abstract no. P-8713]. Eur J Cancer Suppl 2009 Sep; 7(2): 497
Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as mono therapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 Feb 1; 65(3): 671–80
Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct 15; 57(20): 4593–9
Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7(4): 335–45
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 Apr 29; 362(6423): 841–4
Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 Feb 1; 19(3): 843–50
Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006 Nov;28(11): 1779–802
Jain RK. A new target for tumor therapy. N Engl J Med 2009 Jun 18; 360(25): 2669–71
Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008 Oct; 62(5): 779–86
Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001 Feb 1; 19(3): 851–6
Denlinger CS, Blanchard R, Xu L, et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009 Dec; 65(1): 97–105
Mahmood I. Center for Drug Evaluation and Research. Approval package for application number STN-125085/0: clinical pharmacology/TOX review [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_BioPharmr.pdf [Accessed 2009 Sep3]
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 Oct 1; 27(28): 4733–40
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009 Feb 10; 27(5): 740–5
US Food and Drug Administration. FDA briefing document: Oncology Drug Advisory Committee meeting; March 31, 2009; BLA STN 125085/169 Avastin® (bevacizumab) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4427b1-01-FDA.pdf [Accessed 2009 Aug 12]
Macdonald DR, Cascino TL, Schold Jr SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990 Jul; 8(7): 1277–80
Prados M, Cloughesy T, Samant MK, et al. Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN study [abstract no. P-8721]. Eur J Cancer Suppl 2009 Sep; 7(2): 499
Vredenburgh JJ, Wefel J, Cloughesy T, et al. Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study [abstract no. O-8707]. Eur J Cancer Suppl 2009 Sep; 7(2): 495
Wefel JS, Cloughesy T, Zazzali J, et al. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study [abstract no. 2056]. J Clin Oncol 2009; 27 Suppl.: 15s. Plus poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)
Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anti-cancer Ther 2009 Jul; 9(7): 999–1007
Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas: efficacy and safety issues. Curr Opin Neurol 2008 Dec; 21(6): 736–44
Acknowledgements and Disclosures
The manuscript was reviewed by: H.S. Friedman, Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA; T.N. Kreisl, Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA; P.Y. Wen, Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
About this article
Cite this article
Moen, M.D. Bevacizumab. Drugs 70, 181–189 (2010). https://doi.org/10.2165/11203890-000000000-00000
- Vascular Endothelial Growth Factor
- Objective Response Rate
- Karnofsky Performance Status